Breaking News, Collaborations & Alliances

Amgen, Kite in Next-Gen Immunotherapy Pact

Aims to develop and commercialize next-gen (CAR) T cell immunotherapies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen and Kite Pharma have entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite’s engineered autologous cell therapy (eACT) platform and Amgen’s cancer targets.   Amgen will contribute cancer targets and Kite will use its CAR platform, R&D and manufacturing capabilities to conduct preclinical research, cell manufacturing and processing th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters